Survodutide

GLP-1 + glucagon dual agonist · Boehringer Ingelheim

Top dose
6 mg
Weight loss
-16.6%
at week 76 · efficacy
AE discontinuation
24.8%
Status
phase 3

Weight loss trajectory #

Weight loss trajectory for Survodutide 6 mg over 76 weeks in the SYNCHRONIZE-1 trial.

Pivotal trial #

Trial
SYNCHRONIZE-1
Indication
obesity (no T2D)
Duration
76 weeks
ClinicalTrials.gov
NCT06066515
Sponsor
Boehringer Ingelheim

Dose-response: weight loss vs AE-led discontinuation #

Per-arm efficacy (bars, left axis) and AE-led discontinuation (dots, right axis) from SYNCHRONIZE-1 (Le Roux NEJM 2026). Higher doses generally trade extra weight loss for worse tolerability.

Notes #

Highest AE discontinuation in class. -34% visceral fat, -63% liver fat (MRI subgroup).